Concord Biotech CONCORDBIO.NS · INR

Its shares trade on NSE under the ticker CONCORDBIO.NS. It has been listed since 18 August 2023. In the fiscal year to 31 March 2026, it reported revenue of ₹10.55bn and net income of ₹2.61bn. At that date it held total assets of ₹22.35bn and shareholders' equity of ₹20.17bn.

Concord Biotech Ltd is a IN-based company operating in Pharmaceuticals industry. The company is headquartered in Ahmedabad, Gujarat. The company went IPO on 2023-08-18. Concord Biotech Limited is an India-based research and development driven biopharma company. The firm is engaged in the research and development, manufacturing, marketing, and selling of pharmaceutical products. The firm manufactures active pharmaceutical ingredients (API) through fermentation and semi-synthetic processes and finished formulations. The company manufactures fermentation and semi-synthetic based products in the therapeutic segments, such as immunosuppressants, anti-bacterial, oncology, anti-fungal and others. Its API products include Mycophenolate Mofetil, Mycophenolate Sodium, Cyclosporine, Vancomycin Hydrochloride, Micafungin Sodium, Mupirocin, Romidepsin, Dactinomycin, and Pravastatin Sodium, among others. The company also has a pipeline of API products under development. Its API products under development include Polymyxin B, Fidaxomicin, Doxorubicin, and others. The firm provides products in the critical care, immunology, nephrology, and transplant medicine segments.

Figures and description from our data supplier, not checked against the company's own report.

• Mr. Sudhir VaidExecutive Chairman of the Board, Managing Director₹50.2m
• Mr. Ankur VaidChief Executive Officer, Joint Managing Director, Executive Director₹28.9m
• Mr. Raviraj KariaChief Financial Officer
• Mr. Paritosh TrivediCompliance Officer, Company Secretary
• Mr. Devang BhattVice President - Sales and Marketing, Head - Limbasi Plant - 3
• Dr. Manoj KumarVice-President - Formulation Division and Head - Valthera Unit - 2
• Mr. Sundeep BenganiGeneral Manager - International Business Development, Formulation Division
• Mr. Rajiv AgarwalNon-Executive Nominee Director₹220,000
• Mr. Ravi KapoorNon-Executive Director₹220,000
• Shri. Arvind AgarwalNon-Executive Independent Director₹200,000
• Mr. Jayaram EaswaranNon-Executive Independent Director₹200,000
• Mrs. Bharti KhannaNon-Executive Independent Director₹170,000

Overall

0

Environment

0

Social

0

Governance

0

Data on this tab

Our data supplier

Chart on the Overview

TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.